$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000139047813000031 Filed on November 06, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$1.436M	$2.166M	$2.166M
YoY Change	0.0%	0.0%
Cost Of Revenue	$220.0K	$258.0K	$0.00
YoY Change
Gross Profit	$1.229M	$1.454M	$1.454M
YoY Change	0.0%	0.0%
Gross Profit Margin	85.58%	67.13%	67.13%
Selling, General & Admin	$6.230M	$4.129M	$1.360M
YoY Change	323.81%	203.6%	-34.3%
% of Gross Profit	506.92%	283.98%	93.54%
Research & Development	$7.090M	$3.633M	$4.169M
YoY Change	72.51%	-12.86%	204.97%
% of Gross Profit	576.89%	249.86%	286.73%
Depreciation & Amortization	$120.0K	$130.0K	$10.00K
YoY Change		1200.0%	-80.0%
% of Gross Profit	9.76%	8.94%	0.69%
Operating Expenses	$13.45M	$7.762M	$5.528M
YoY Change	141.04%	40.41%	60.93%
Operating Profit	-$12.22M	-$6.893M	-$5.528M
YoY Change	180.88%	24.69%
Interest Expense	-$34.66M	-$1.110M	-$260.0K
YoY Change		326.92%	-75.24%
% of Operating Profit
Other Income/Expense, Net	-$380.0K	-$8.128M	-$733.0K
YoY Change	-149.35%	1008.87%	84.63%
Pretax Income	-$47.39M	-$8.128M	-$6.261M
YoY Change	887.29%	29.82%	63.47%
Income Tax	$1.110M	$1.159M
% Of Pretax Income
Net Earnings	-$5.516M	-$6.929M	-$18.03M
YoY Change	-71.97%	-61.56%	229.24%
Net Earnings / Revenue	-384.12%	-319.9%	-832.23%
Basic Earnings Per Share	-$0.51	-$0.66	-$2.23
Diluted Earnings Per Share	-$13.64B	-$3.191B	-$2.792B
COMMON SHARES
Basic Shares Outstanding	105.2M shares	84.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$47.79M	$54.23M	$15.40M
YoY Change	34.67%	252.16%	-1.91%
Cash & Equivalents	$47.79M	$51.40M	$51.40M
Short-Term Investments	$0.00	$2.837M
Other Short-Term Assets	$1.600M	$600.0K	$900.0K
YoY Change	166.67%	-33.33%	80.0%
Inventory	$386.0K	$425.0K
Prepaid Expenses
Receivables	$3.683M	$1.543M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$68.79M	$56.79M	$16.33M
YoY Change	90.43%	247.85%	0.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$314.0K	$545.0K	$31.00K
YoY Change	982.76%	1658.06%	-92.25%
Goodwill	$5.898M	$5.898M	$5.898M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$19.19M	$34.47M	$18.87M
YoY Change	1.73%	82.69%	33.81%
TOTAL ASSETS
Total Short-Term Assets	$68.79M	$56.79M	$16.33M
Total Long-Term Assets	$19.19M	$34.47M	$18.87M
Total Assets	$87.98M	$91.25M	$35.19M
YoY Change	60.0%	159.3%	16.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.907M	$1.890M	$2.210M
YoY Change	-3.49%	-14.48%	47.33%
Accrued Expenses	$4.841M	$8.889M	$2.012M
YoY Change	137.54%	341.8%	18.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.149M	$1.215M	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$62.47M	$36.51M	$10.06M
YoY Change	292.44%	263.07%	-53.22%
LONG-TERM LIABILITIES
Long-Term Debt	$7.743M	$8.583M	$100.0K
YoY Change		8483.0%
Other Long-Term Liabilities	$6.800M	$6.500M	$5.900M
YoY Change	9.68%	10.17%	43.9%
Total Long-Term Liabilities	$7.743M	$8.583M	$6.000M
YoY Change		43.05%	46.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.47M	$36.51M	$10.06M
Total Long-Term Liabilities	$7.743M	$8.583M	$6.000M
Total Liabilities	$82.09M	$56.63M	$21.03M
YoY Change	201.47%	169.34%	-17.86%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$188.6M	$167.1M	$116.5M
YoY Change	42.7%	43.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M	$3.849M
YoY Change	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares	675.0K shares
Shareholders Equity	$5.886M	$34.62M	$14.17M
YoY Change
Total Liabilities & Shareholders Equity	$87.98M	$91.25M	$35.19M
YoY Change	60.0%	159.3%	16.15%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$5.516M	-$6.929M	-$18.03M
YoY Change	-71.97%	-61.56%	229.24%
Depreciation, Depletion And Amortization	$120.0K	$130.0K	$10.00K
YoY Change		1200.0%	-80.0%
Cash From Operating Activities	-$8.490M	-$7.990M	-$4.170M
YoY Change	64.22%	91.61%	22.29%
INVESTING ACTIVITIES
Capital Expenditures	-$5.220M	-$100.0K	$0.00
YoY Change
Acquisitions	$10.00M	$10.00M
YoY Change
Other Investing Activities	$2.420M	$810.0K	$0.00
YoY Change
Cash From Investing Activities	-$2.800M	$720.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.690M	37.74M	360.0K
YoY Change	-65.91%	10383.33%	-69.49%
NET CHANGE
Cash From Operating Activities	-8.490M	-7.990M	-4.170M
Cash From Investing Activities	-2.800M	720.0K	0.000
Cash From Financing Activities	7.690M	37.74M	360.0K
Net Change In Cash	-3.600M	30.47M	-3.810M
YoY Change	-120.7%	-899.74%	70.85%
FREE CASH FLOW
Cash From Operating Activities	-$8.490M	-$7.990M	-$4.170M
Capital Expenditures	-$5.220M	-$100.0K	$0.00
Free Cash Flow	-$3.270M	-$7.890M	-$4.170M
YoY Change		89.21%	22.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1890000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1976000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1543000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8889000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2038000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	116000	USD
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	150000	USD
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	USD
CY2013Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	141000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1626000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1722000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	167111000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	132168000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1066000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	461000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	364000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1316000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1344000	USD
CY2013Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43	USD
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28831000	shares
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13287000	shares
CY2013Q3	us-gaap	Assets Assets	91254000	USD
CY2012Q4	us-gaap	Assets Assets	54986000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	56786000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	36121000	USD
	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	993000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	30000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	51000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51396000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32807000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11433000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15423000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	50877000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18589000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3990000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.47
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.50
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.35	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18903000	shares
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13216000	shares
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	34891000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83595837	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105588771	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	104913771	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82920837	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits		USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;"> — Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the company’s cash equivalents were invested in money market mutual funds. The company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents.</font></div></div>
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	301000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	301000	USD
CY2012Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2013Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15000000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0845
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-63000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2013Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	129000	USD
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	74000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000	USD
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> — Historically, the company has from time to time granted warrants to vendors as consideration for their services. We may also issue warrants as part of a debt or equity financing. The company does not enter into any derivative contracts for speculative purposes.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company recognizes all derivatives as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with FASB ASC Topic 815-40, “ </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging — Contracts in Entity’s Own Stock,”</font><font style="font-family:inherit;font-size:10pt;"> the value of warrants that are deemed to meet the definition of derivatives are required to be recorded as a liability, as the holders have an option to put the warrants back to the company upon the occurrence of certain events described in the warrants.</font></div></div>
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	217000	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1161000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7Y
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
	us-gaap	Gain Loss On Sale Of Securities Net GainLossOnSaleOfSecuritiesNet	1392000	USD
	us-gaap	Gain Loss On Sale Of Securities Net GainLossOnSaleOfSecuritiesNet	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8369000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4129000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1359000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5068000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2013Q3	us-gaap	Goodwill Goodwill	5898000	USD
	us-gaap	Gross Profit GrossProfit	0	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	869000	USD
	us-gaap	Gross Profit GrossProfit	869000	USD
CY2012Q3	us-gaap	Gross Profit GrossProfit	0	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-28177000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-29574000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9287000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6261000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-28239000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8128000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-29574000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6261000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.49
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.33
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.09
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.11
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2013Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1644000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.03
CY2013Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1159000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-62000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-86000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	875000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1543000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-165000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1975000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	425000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	662000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-68000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1000	USD
	us-gaap	Interest Paid InterestPaid	-195000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2013Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	155000	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	425000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2013Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	270000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	27230000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	56634000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91254000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54986000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15919000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	36514000	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1215000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8583000	USD
CY2013Q3	us-gaap	Marketable Securities MarketableSecurities	2837000	USD
CY2012Q4	us-gaap	Marketable Securities MarketableSecurities	2678000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	1392000	USD
CY2012Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2013Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	814000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1551000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19872000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48262000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9236000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15795000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20437000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-6261000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31218000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-9287000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28177000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	-5000000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1		USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-733000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1795000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13953000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6749000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1235000	USD
	us-gaap	Operating Expenses OperatingExpenses	22359000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	7762000	USD
	us-gaap	Operating Expenses OperatingExpenses	15621000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	5528000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6893000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21490000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15621000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5528000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	643000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6261000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-31218000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28080000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11078000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	-1636000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	-841000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	-330000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	-643000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax		USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax		USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-2108000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1089000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-828000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	705000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-733000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-921000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13918000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6254000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	266000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants		USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10075000	USD
CY2013Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10086000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	554000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	485000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	535000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div>
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	13000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37520000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13937000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9865000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	35000000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5200000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1392000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	545000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	10000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	21000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4169000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3633000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13990000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10553000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13599000	USD
CY2013Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3500000	USD
CY2012Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4074000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10168000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	7120000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	101000	USD
	us-gaap	Sales Discounts Services SalesDiscountsServices	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1170000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1170000	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0125
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7535
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7766
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0106
	us-gaap	Share Based Compensation ShareBasedCompensation	1068000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1344000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7567
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0085
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6271000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.65
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	517000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2783000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.28
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6867000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9928000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7672000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.54
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.26
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4257000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.88
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.39
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.88
CY2013Q3	us-gaap	Share Price SharePrice	2.00
CY2012Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	gale	Interest Income InterestIncome	-35000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	27756000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	34620000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27756000	USD
CY2013Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34620000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M17D
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	17500000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10000	shares
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2890000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	69000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	211000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37520000	USD
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2013Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> — The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div>
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67265470	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87319450	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84678612	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60150658	shares
CY2013Q3	gale	Amortization Period Of Selling And Distribution Rights AmortizationPeriodOfSellingAndDistributionRights	P10Y
CY2011Q3	gale	Cash Contribution In Capital CashContributionInCapital	1500000	USD
	gale	Cash Transferred With Spin Off Transaction CashTransferredWithSpinOffTransaction	87000	USD
	gale	Cash Transferred With Spin Off Transaction CashTransferredWithSpinOffTransaction		USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-11899000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-7135000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-559000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-2019000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	2019000	USD
CY2012Q3	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	471000	USD
CY2012Q3	gale	Changeinfairvalueofwarrantspotentiallysettleableincash Changeinfairvalueofwarrantspotentiallysettleableincash	262000	USD
	gale	Changeinfairvalueofwarrantspotentiallysettleableincash Changeinfairvalueofwarrantspotentiallysettleableincash	11899000	USD
	gale	Changeinfairvalueofwarrantspotentiallysettleableincash Changeinfairvalueofwarrantspotentiallysettleableincash	7135000	USD
CY2013Q3	gale	Changeinfairvalueofwarrantspotentiallysettleableincash Changeinfairvalueofwarrantspotentiallysettleableincash	1614000	USD
CY2013Q3	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	172000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	559000	USD
	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	1349000	shares
CY2013Q2	gale	Classof Warrantor Right Average Market Price Used For Exercise Price ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice	P20D
	gale	Classof Warrantor Right Expired ClassofWarrantorRightExpired	190000	shares
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	7226000	shares
CY2013Q2	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P7Y
CY2013Q3	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	756000	shares
	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	-39000	USD
	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	-69000	USD
CY2012Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6207000	USD
CY2013Q3	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6454000	USD
CY2013Q3	gale	Contract Research Payable ContractResearchPayable	1559000	USD
CY2012Q4	gale	Contract Research Payable ContractResearchPayable	1705000	USD
CY2013Q3	gale	Current Contingent Purchase Price Consideration CurrentContingentPurchasePriceConsideration	247000	USD
CY2012Q4	gale	Current Contingent Purchase Price Consideration CurrentContingentPurchasePriceConsideration	935000	USD
CY2013Q2	gale	Debt Instrument Cash Facility Fee DebtInstrumentCashFacilityFee	0.01
CY2013Q2	gale	Debt Instrument Cash Final Payment DebtInstrumentCashFinalPayment	0.055
CY2013Q2	gale	Debt Instrument Term DebtInstrumentTerm	P30M
CY2013Q2	gale	Debt Instrument Term Interest Only DebtInstrumentTermInterestOnly	P12M
CY2013Q3	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-130374000	USD
CY2012Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-102197000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	2955000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y10M10D
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices		USD
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	342000	USD
	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	-2055000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity		USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	8238000	USD
CY2013Q3	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	24267000	USD
CY2012Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	10964000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	1.93
CY2012Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	10964000	USD
CY2013Q3	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	24267000	USD
	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	8238000	USD
CY2012Q4	gale	Future Milestone Payment FutureMilestonePayment	0	USD
CY2013Q3	gale	Future Milestone Payment FutureMilestonePayment	5000000	USD
CY2012Q3	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	85000	USD
CY2013Q3	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	328000	USD
	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	366000	USD
	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	742000	USD
	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	7416000	USD
CY2012Q3	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	1090000	USD
CY2013Q3	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	3801000	USD
	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	4137000	USD
CY2012Q3	gale	General And Administrative Non Employee Stock Based Compensation Expense GeneralAndAdministrativeNonEmployeeStockBasedCompensationExpense	184000	USD
CY2013Q3	gale	General And Administrative Non Employee Stock Based Compensation Expense GeneralAndAdministrativeNonEmployeeStockBasedCompensationExpense	0	USD
	gale	General And Administrative Non Employee Stock Based Compensation Expense GeneralAndAdministrativeNonEmployeeStockBasedCompensationExpense	565000	USD
	gale	General And Administrative Non Employee Stock Based Compensation Expense GeneralAndAdministrativeNonEmployeeStockBasedCompensationExpense	211000	USD
CY2012Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2013Q3	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2012Q3	gale	Interest Income InterestIncome	0	USD
CY2013Q3	gale	Interest Income InterestIncome	-314000	USD
	gale	Interest Income InterestIncome	-495000	USD
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	1579000	USD
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	1000000	USD
CY2013Q3	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
	gale	Minimum Likely Hood For More Likely Than Not Threshold MinimumLikelyHoodForMoreLikelyThanNotThreshold	0.50
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	48000	USD
CY2012Q3	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
CY2013Q3	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	51000	USD
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
	gale	Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOffNetOfCashTransferredInSpinOff	2246000	USD
	gale	Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOffNetOfCashTransferredInSpinOff	0	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	820000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	5672000	USD
	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable		USD
	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable	-500000	USD
CY2013Q3	gale	Numberof Commerical Products NumberofCommericalProducts	1	products
CY2013Q2	gale	Numberof Days Averagedfor Exercise Price NumberofDaysAveragedforExercisePrice	P20D
CY2013Q3	gale	Numberof Dosing Strengths NumberofDosingStrengths	6	dosing_strength
CY2013Q3	gale	Numberof Shares Per Unit NumberofSharesPerUnit	1	shares
CY2013Q3	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	5304000	shares
CY2012Q4	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	0	USD
CY2013Q3	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	808000	USD
CY2013Q3	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	37500000	USD
	gale	Proceeds From Technology Revenue ProceedsFromTechnologyRevenue	45000000	USD
	gale	Proceeds From Technology Revenue Under Condition One ProceedsFromTechnologyRevenueUnderConditionOne	15000000	USD
	gale	Proceeds From Technology Revenue Under Condition Two ProceedsFromTechnologyRevenueUnderConditionTwo	30000000	USD
CY2013Q3	gale	Proceedsfromsaleofsharesafterspinoff Proceedsfromsaleofsharesafterspinoff	814000	USD
	gale	Proceedsfromsaleofsharesafterspinoff Proceedsfromsaleofsharesafterspinoff	1392000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	2070000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	10741000	USD
	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	324000	USD
	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	138000	USD
CY2013Q3	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	117000	USD
CY2012Q3	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	48000	USD
	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	67000	USD
	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	247000	USD
CY2012Q3	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	47000	USD
CY2013Q3	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	16000	USD
CY2012Q4	gale	Sales And Distributions Rights SalesAndDistributionsRights		USD
CY2013Q3	gale	Sales And Distributions Rights SalesAndDistributionsRights	15032000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	37000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	1203000	USD
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	182186	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	105236516	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
	dei	Trading Symbol TradingSymbol	GALE

Files In Submission

Name	View Source	Status
0001390478-13-000031-index-headers.html	Edgar Link	pending
0001390478-13-000031-index.html	Edgar Link	pending
0001390478-13-000031.txt	Edgar Link	pending
0001390478-13-000031-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gale-20130930.xml	Edgar Link	completed
gale-20130930.xsd	Edgar Link	pending
gale-20130930x10q.htm	Edgar Link	pending
gale-20130930_cal.xml	Edgar Link	unprocessable
gale-20130930_def.xml	Edgar Link	unprocessable
gale-20130930_lab.xml	Edgar Link	unprocessable
gale-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2013 Q4 Form 10-Q Financial Statement

#000139047813000031 Filed on November 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2013 Q4 Form 10-Q Financial Statement

#000139047813000031 Filed on November 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls